In the news
What's changing for GLP-1 medications, in Canada and worldwide. Each update is dated, links to its primary sources, and explains what it means for you.
Latest updates
Survodutide phase 3 resultsBoehringer Ingelheim said on 1 October 2026 that its phase 3 trial of survodutide met both co-primary endpoints. It isn't on Health Canada's review list.Wegovy and MASH: new liver analysisNovo Nordisk reported an exploratory Wegovy liver analysis on 1 October 2026. Here is what the Canadian monograph says about MASH and what has not changed.Orforglipron heart safety trialLilly says its oral GLP-1 orforglipron met the goal of ACHIEVE-4, a heart-safety trial. It isn't authorized in Canada. What the result does and doesn't mean.Retatrutide phase 3 resultsLilly presented phase 3 results for retatrutide, a triple agonist, on 30 September 2026. It isn't on Health Canada's review list, and Lilly plans a US filing.Insurers report rising GLP-1 costsGreenShield (29 September 2026) and Medavie Blue Cross reported 2025 drug plan costs for semaglutide and weight-management drugs. What it means for your plan.Orforglipron and CagriSema under reviewHealth Canada's list shows Lilly's orforglipron and Novo's CagriSema accepted for review in 2026. What under review means, and why approval isn't coverage.GLP-1 supply and new capacity plansNovo Nordisk and Eli Lilly announced GLP-1 manufacturing plans on 21 September 2026. Here is what more capacity could mean for GLP-1 supply in Canada.Sandoz generic Ozempic approvedHealth Canada authorized Sandoz Semaglutide, a generic Ozempic for type 2 diabetes. Sandoz announced it on 18 September 2026 and gave no price or launch date.Pharmacy chains report GLP-1 growthThe Canadian Press reported on 13 September 2026 that Loblaw and Metro pharmacies saw GLP-1 sales growth. Here is what that does and doesn't mean for prices.Zepbound's path to public coverageOn 3 September 2026 the pCPA acknowledged Zepbound after Canada's Drug Agency recommended it with conditions. How public coverage is decided and what's next.
We cover news that changes what Canadians can get, what it costs, or who pays for it: Health Canada approvals, generic launches, provincial and private coverage decisions, pricing, and late-stage research that may reach Canada. We don’t report weight-loss figures or compare how well medications work. See our editorial policy.